Fennec Pharmaceuticals’ Pedmark gets FDA breakthrough status

This article was originally published here

Fennec Pharmaceuticals has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for Pedmark to prevent cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply